Related Experiment Video
Updated: Aug 27, 2025
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma
Lijun Peng1,2,3, Huapan Fang4, Xiao Yang5
1Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, China.
Abstract:
One of the most common primary bone malignant tumors is osteosarcoma (OS), possessing a high tendency of local invasion and distant metastasis. Although surgery combined with chemotherapy can extend the patients' survival time, the prognosis for most patients with metastases or relapses is poor. Immunotherapy has been proved to be a promising treatment alternative for malignant tumors. Although there is a significant amount of animal- and cell-based evidence supporting the relationship between immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) and cancers, no pan-cancer analysis is available. Simultaneously, immune checkpoint inhibitors have demonstrated satisfactory clinical results in some tumors; however, only a small fraction of patients with certain cancer types have been benefitted. Therefore, based on the TCGA dataset, we first explored the potential roles of immune checkpoints in 33 tumors. Programmed death receptor 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) were not consistently expressed in the same direction in all tumors; however, the direction of expression change was the same in most immune cells. Although there is no well-established relationship between the expression of PD-1/PD-L1/CTLA-4 genes and the prognosis of patients with sarcomas, their interaction and extent of immune cell infiltration into sarcomas are probably the key determinants of therapeutic response. Our first pan-cancer study provides a relatively comprehensive understanding of immune checkpoint inhibitors in different sarcomas.
Insights
This study analyzed immune checkpoints like PD-1 and CTLA-4 across 33 cancers. Findings suggest their expression and immune cell infiltration are key for sarcoma treatment response.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Osteosarcoma (OS) is a common bone cancer with poor prognosis, especially with metastasis.
- Immunotherapy, including immune checkpoint inhibitors, shows promise for cancer treatment.
- Existing research on immune checkpoints (anti-PD-1, anti-PD-L1, anti-CTLA-4) lacks a pan-cancer analysis.
Purpose of the Study:
- To conduct the first pan-cancer analysis of immune checkpoints (PD-1, PD-L1, CTLA-4) using TCGA data.
- To explore the potential roles and expression patterns of these immune checkpoints across 33 tumor types.
- To investigate the relationship between immune checkpoints and sarcoma prognosis and therapeutic response.
Main Methods:
- Utilized The Cancer Genome Atlas (TCGA) dataset for comprehensive analysis.
- Examined the expression levels and patterns of programmed death receptor 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) across 33 cancer types.
- Correlated gene expression with immune cell infiltration and patient prognosis.
Main Results:
- Expression of PD-1, PD-L1, and CTLA-4 varied across different tumors, but expression changes in immune cells showed consistent directionality.
- No established link between PD-1/PD-L1/CTLA-4 gene expression and sarcoma patient prognosis was found.
- Immune cell infiltration and checkpoint interactions are likely crucial for predicting therapeutic response in sarcomas.
Conclusions:
- This pan-cancer study offers a broad understanding of immune checkpoint roles in various sarcomas.
- Immune checkpoint expression and immune microenvironment characteristics are critical factors for optimizing immunotherapy in sarcomas.
- Further research is warranted to elucidate the precise mechanisms governing immune checkpoint inhibitor efficacy in different cancer types.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...